title: Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.
abstract: In August 1997, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened an expert working group to discuss current strategies for the development of HIV type 1 vaccines. Based on the recent findings of investigators from Japan's National Institute of Infectious Diseases (NIID) in Tokyo using recombinant bacillus Calmette-Guérin (rBCG) as a potential vectored vaccine for HIV, a recommendation was made that further work in this area is a priority. As a result, the working group reconvened in September 1998 to discuss the progress to date with this vaccine approach, as well as areas of related research to assess the feasibility of a BCG-vectored HIV vaccine. This report summarizes the discussions addressing the available scientific data on the potential use of rBCG as a vector for preventive HIV vaccines, the work necessary to move such candidate vaccines into Phase 1 clinical trials, and recommendations targeted at facilitating the long-term development of rBCG-vectored HIV vaccines.
authors.affiliation: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Rockville, Maryland 20852-1448, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Falk
authors.forename: K L
authors.initials: KL
authors.lastname: Goldenthal
authors.forename: J
authors.initials: J
authors.lastname: Esparza
authors.forename: M T
authors.initials: MT
authors.lastname: Aguado
authors.forename: S
authors.initials: S
authors.lastname: Osmanov
authors.forename: W R
authors.initials: WR
authors.lastname: Ballou
authors.forename: S
authors.initials: S
authors.lastname: Beddows
authors.forename: N
authors.initials: N
authors.lastname: Bhamarapravati
authors.forename: G
authors.initials: G
authors.lastname: Biberfeld
authors.forename: G
authors.initials: G
authors.lastname: Ferrari
authors.forename: D
authors.initials: D
authors.lastname: Hoft
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: A
authors.initials: A
authors.lastname: Jackson
authors.forename: Y
authors.initials: Y
authors.lastname: Lu
authors.forename: G
authors.initials: G
authors.lastname: Marchal
authors.forename: J
authors.initials: J
authors.lastname: McKinney
authors.forename: S
authors.initials: S
authors.lastname: Yamazaki
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D005822:Genetic Vectors; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D014480:United Nations; D014614:Vaccines, Synthetic / Q000276:immunology; D014944:World Health Organization
chemical_list: D016915:AIDS Vaccines; D001500:BCG Vaccine; D014614:Vaccines, Synthetic